NKNorman Koglin

Norman Koglin

*This is an algorithmically generated author record based on publicly available information.

Norman Koglin has a total of 207 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Noninvasive Thrombus Imaging in Patients With Ischemic Stroke

    by Beth Whittington, Craig Balmforth, Alessandro Giaj Levra, Laura Clark, Neil Craig, Audrey White, Krithika Loganath, Evangelos Tzolos, Allison Winarski, Rachael O. Forsythe, et al.

    BACKGROUND: Determining the source of thromboembolism in patients with acute ischemic stroke remains challenging because current diagnostic approaches rely largely on circumstantial and inferential associations rather than direct identification of the cause of stroke. Fluorine-18 GP1 ([ 18 F]GP1) is a novel radiotracer that binds with high affinity and specificity to activated glycoprotein IIb/IIIa receptors on activated platelets. We aimed to determine whether hybrid [ 18 F]GP1 positron emission tomography (PET) and computed tomography angiography could identify in vivo cardiovascular thromboembolism in patients with acute ischemic stroke and provide a mechanism-based assessment of stroke etiology. METHODS: In a single-center prospective observational cohort study, 100 patients presenting with acute ischemic stroke underwent hybrid [ 18 F]GP1 PET/computed tomography angiography within 21 days of symptom onset in addition to standard-of-care stroke investigations. Stroke etiology was classified using the causative classification system by an expert stroke physician blinded to [ 18 F]GP1 PET findings. In parallel, [ 18 F]GP1 PET/computed tomography angiography images were analyzed independently by readers who were blinded to all clinical data and causative classification system classification. We assessed whether [ 18 F]GP1 PET/computed tomography angiography could identify the source of in vivo cardiovascular thromboembolism, influence stroke classification, and predict recurrent cerebrovascular events. RESULTS: Cardiovascular [ 18 F]GP1 uptake indicative of thrombosis was identified in nearly two-thirds (n=63) of participants, changing stroke classification in over a quarter (n=26) of patients. In those with stroke of undetermined cause, the source of thrombus was identified in 18 of 41 (44%) participants, which included nonstenotic carotid atherothrombosis, native cardiac valve thrombosis, and paradoxical thromboembolism. During a median follow-up of 613 (interquartile interval, 251–788) days, recurrent stroke or transient ischemic attack occurred in 14 patients, 13 (93%) of whom had cardiovascular [ 18 F]GP1 uptake at baseline. Cardiovascular [ 18 F]GP1 uptake was associated with a 10.4-fold increased risk of recurrent events (95% CI, 1.35–79.40; P =0.024). CONCLUSIONS: Noninvasive thrombosis imaging is a novel technique that enables direct in vivo identification of thrombus formation and frequently reveals the source of thromboembolism in patients with acute ischemic stroke. This approach represents a shift from inference-based to mechanism-based stroke classification with potential implications for targeted prevention strategies and better patient outcomes. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT05636748.


  • Open Access

    Platelet activation and thrombosis in microvascular obstruction

    by Craig Balmforth, Alessandro Giaj Levra, Beth Whittington, Aidan Morgan, Mark G Macaskill, Evangelos Tzolos, Alex J Jordan, Tariq Ramtoola, Tim Clark, Michelle Rooney, et al.

    Aims: Microvascular obstruction (MVO) remains a major complication following coronary reperfusion, but its pathogenesis is poorly defined. We evaluated myocardial platelet activation and thrombosis using fluorine-18-labelled GP1 ([18F]GP1) positron emission tomography (PET) in patients with anterior ST-segment elevation myocardial infarction. Methods and results: In a single-centre observational cohort study, 100 patients with acute anterior ST-segment elevation myocardial infarction underwent hybrid cardiac [18F]GP1 PET and magnetic resonance (MR) imaging with gadolinium enhancement and repeat imaging at 3–6 months. Myocardial [18F]GP1 uptake was quantified using target-to-background ratio (TBRmax) and percentage myocardial uptake (burden) and compared with MR measures of infarction, MVO and adverse ventricular remodelling. One hundred patients (60 ± 10 years, 91% male) underwent [18F]GP1 PET/MR imaging at a median of 13 days following index presentation. Increased myocardial [18F]GP1 uptake was observed in 44% of participants (TBRmax 1.89 ± 0.50). All 40 patients with MR-defined MVO demonstrated myocardial [18F]GP1 uptake. Myocardial [18F]GP1 uptake burden correlated with (ρ = 0.84; P < 0.001), and exceeded (by 18%), MR-defined burden of MVO. Myocardial [18F]GP1 uptake was associated with infarct size, lower left ventricular ejection fraction and longer time-to-reperfusion. Angiographic no-reflow was the strongest independent association of MVO (adjusted odds ratio 16.15; P < 0.001). Persistent myocardial [18F]GP1 uptake at follow up (22%, 7/32) was associated with lower left ventricular ejection fraction. Resolution of cardiac MR-defined MVO was observed in 78% of patients at follow-up and was universally concordant with resolution of myocardial [18F]GP1 uptake. Conclusion: MVO following ST-segment elevation myocardial infarction is universally associated with myocardial platelet activation, extending beyond structural abnormalities identified by cardiac MR. These findings are consistent with an important mechanistic contribution of platelet-mediated microvascular thrombosis to no-reflow and MVO, highlighting a potentially targetable biological pathway in a condition for which effective therapies remain elusive.


  • Open Access

    Quantification of baseline amyloid PET in individuals with subjective cognitive decline can identify risk of amyloid accumulation and cognitive worsening: the FACEHBI study

    by Guilherme Domingues Kolinger, Oscar Sotolongo-Grau, Núria Roé-Vellvé, Juan Pablo Tartari, Ángela Sanabria, Esther Pérez-Martínez, Norman Koglin, Andrew W. Stephens, Montserrat Alegret, Lluís Tárraga, et al.

    Purpose: Amyloid PET imaging is capable of measuring brain amyloid load in vivo. The aim of this study is to assess the relationship of the baseline amyloid with its accumulation over time and with cognition in individuals with subjective cognitive decline (SCD), giving a focus on those below Aβ positivity thresholds. Methods: 118 of 197 individuals with SCD from the Fundació ACE Healthy Brain Initiative underwent three [18F]florbetaben scans and the remaining 79 underwent two scans in a 5-year span. Individuals were categorised based on baseline Centiloid values (CL) into amyloid positive (Aβ+; CL > 35.7), Grey Zone (GZ; 20 < CL ≤ 35.7), and amyloid negative (Aβ-; CL ≤ 20). Relationship between conversion to mild cognitive decline (MCI) and baseline amyloid levels was assessed. Then, to focus on sub-threshold individuals with amyloid accumulation, the Aβ- group was split into two groups (N1 (CL ≤ 13.5) and N2 (13.5 < CL ≤ 20)), Aβ accumulation was determined, and a parametric image analysis of the Aβ accumulators in the N1 group was performed. Results: At baseline, 20 individuals were Aβ+, 8 GZ, 160 N1, and 9 N2. Higher Aβ load, older and less educated individuals presented increased risk of MCI-conversion. Longitudinally, 19% of N1 individuals were accumulators despite very low Aβ burden at baseline. Meanwhile, 89% of the N2 group accumulated Aβ as well as all GZ individuals (which had the highest rate of amyloid accumulation, 5.1 CL/year). In the parametric image analysis of N1 accumulators, a region within the precuneus was linked to increased Aβ over time. Conclusion: Baseline amyloid levels differentiate individuals who accumulate amyloid over time and that are at risk for cognitive decline, including those at sub-threshold levels of Aβ. This can be valuable to identify pre-clinical AD in a SCD population.


  • Open Access

    Experiences from Clinical Research and Routine Use of Florbetaben Amyloid PET—A Decade of Post-Authorization Insights

    by Aleksandar Jovalekic, Santiago Bullich, Núria Roé-Vellvé, Guilherme Domingues Kolinger, Lorelei R. Howard, Floriana Elsholz, Mariana Lagos-Quintana, Beatriz Blanco-Rodriguez, Esther Pérez-Martínez, Rossella Gismondi, et al.

    Florbetaben (FBB) is a radiopharmaceutical approved by the FDA and EMA in 2014 for the positron emission tomography (PET) imaging of brain amyloid deposition in patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) or other causes of cognitive decline. Initially, the clinical adoption of FBB PET faced significant barriers, including reimbursement challenges and uncertainties regarding its integration into diagnostic clinical practice. This review examines the progress made in overcoming these obstacles and describes the concurrent evolution of the diagnostic landscape. Advances in quantification methods have further strengthened the traditional visual assessment approach. Over the past decade, compelling evidence has emerged, demonstrating that amyloid PET has a strong impact on AD diagnosis, management, and outcomes across diverse clinical scenarios, even in the absence of amyloid-targeted therapies. Amyloid PET imaging has become essential in clinical trials and the application of new AD therapeutics, particularly for confirming eligibility criteria (i.e., the presence of amyloid plaques) and monitoring biological responses to amyloid-lowering therapies. Since its approval, FBB PET has transitioned from a purely diagnostic tool aimed primarily at excluding amyloid pathology to a critical component in AD drug development, and today, it is essential in the diagnostic workup and therapy management of approved AD treatments.


  • Top Cited Papers
    Open Access

    Centiloid recommendations for clinical context‐of‐use from the AMYPAD consortium

    by Lyduine E. Collij, Ariane Bollack, Renaud La Joie, Mahnaz Shekari, Santiago Bullich, Núria Roé‐Vellvé, Norman Koglin, Aleksandar Jovalekic, David Valléz Garciá, Alexander Drzezga, et al.

    Amyloid‐PET quantification through the tracer‐independent Centiloid (CL) scale has emerged as an essential tool for the accurate measurement of amyloid‐β (Aβ) pathology in Alzheimer's disease (AD) patients. The AMYPAD consortium set out to integrate existing literature and recent work from the consortium to provide clinical context‐of‐use recommendations for the CL scale. Compared to histopathology, visual reads, and cerebrospinal fluid, CL quantification accurately reflects the amount of AD pathology. With high certainty, a CL value below 10 excludes the presence of Aβ pathology, while a value above 30 corresponds well with pathological amounts. Values falling in between these two cutoffs (“intermediate range”) are related to an increased risk of disease progression. Together, CL quantification is a valuable adjunct to visual assessments of amyloid‐PET images. An abnormal amyloid biomarker assessment is a key criterion to determine eligibility for anti‐amyloid disease‐modifying therapies, and amyloid‐PET quantification can add further value by precisely monitoring amyloid clearance, and hence guiding patient management decisions.Highlights: Centiloid (CL) quantification robustly reflects of the amount of Aβ pathology. CL < 10/CL > 30 reflects Aβ‐negativity/positivity thresholds with high certainty. CL quantification is a valuable adjunct to visual assessments of amyloid‐PET. CL quantification can support trial design and treatment management. CL quantification could support the identification of early or emerging Aβ pathology.


  • Open Access

    Clinical [18F]FSPG Positron Emission Tomography Imaging Reveals Heterogeneity in Tumor-Associated System xc− Activity

    by Amy R. Sharkey, Norman Koglin, Erik S. Mittra, Sangwon Han, Gary J. R. Cook, Timothy H. Witney

    Background: (4S)-4-(3-[18F]fluoropropyl)-L-glutamic acid ([18F]FSPG) positron emission tomography/computed tomography (PET/CT) provides a readout of system xc− transport activity and has been used for cancer detection in clinical studies of different cancer types. As system xc− provides the rate-limiting precursor for glutathione biosynthesis, an abundant antioxidant, [18F]FSPG imaging may additionally provide important prognostic information. Here, we performed an analysis of [18F]FSPG radiotracer distribution between primary tumors, metastases, and normal organs from cancer patients. We further assessed the heterogeneity of [18F]FSPG retention between cancer types, and between and within individuals. Methods: This retrospective analysis of prospectively collected data compared [18F]FSPG PET/CT in subjects with head and neck squamous cell cancer (HNSCC, n = 5) and non-small-cell lung cancer (NSCLC, n = 10), scanned at different institutions. Using semi-automated regions of interest drawn around tumors and metastases, the maximum standardized uptake value (SUVmax), SUVmean, SUV standard deviation and SUVpeak were measured. [18F]FSPG time–activity curves (TACs) for normal organs, primary tumors and metastases were subsequently compared to 18F-2-fluoro-2-deoxy-D-glucose ([18F]FDG) PET/CT at 60 min post injection (p.i.). Results: The mean administered activity of [18F]FSPG was 309.3 ± 9.1 MBq in subjects with NSCLC and 285.1 ± 11.3 MBq in those with HNSCC. The biodistribution of [18F]FSPG in both cohorts showed similar TACs in healthy organs from cancer patients. There was no statistically significant overall difference in the average SUVmax of tumor lesions at 60 min p.i. for NSCLC (8.1 ± 7.1) compared to HNSCC (6.0 ± 4.1; p = 0.29) for [18F]FSPG. However, there was heterogeneous retention between and within cancer types; the SUVmax at 60 min p.i. ranged from 1.4 to 23.7 in NSCLC and 3.1–12.1 in HNSCC. Conclusion: [18F]FSPG PET/CT imaging from both NSCLC and HNSCC cohorts showed the same normal-tissue biodistribution, but marked tumor heterogeneity across subjects and between lesions. Despite rapid elimination through the urinary tract and low normal-background tissue retention, the diagnostic potential of [18F]FSPG was limited by variability in tumor retention. As [18F]FSPG retention is mediated by the tumor’s antioxidant capacity and response to oxidative stress, this heterogeneity may provide important insights into an individual tumor’s response or resistance to therapy.


  • Open Access

    Noninvasive In Vivo Thrombus Imaging in Patients With Ischemic Stroke or Transient Ischemic Attack—Brief Report

    by Beth Whittington, Evangelos Tzolos, Rong Bing, Jack Andrews, Christophe Lucatelli, Mark G. MacAskill, Adriana A.S. Tavares, Tim Clark, Nicholas L. Mills, Jennifer Nash, et al.

    BACKGROUND: 18 F-GP1 is a novel positron-emitting radiotracer that is highly specific for activated platelets and thrombus. In a proof-of-concept study, we aimed to determine its potential clinical application in establishing the role and origin of thrombus in ischemic stroke. METHODS: Eleven patients with recent ischemic stroke (n=9) or transient ischemic attack (n=2) underwent 18 F-GP1 positron emission tomography and computed tomography angiography at a median of 11 (range, 2–21) days from symptom onset. 18 F-GP1 uptake (maximum target-to-background ratio) was assessed in the carotid arteries and brain. RESULTS: 18 F-GP1 uptake was identified in 10 of 11 patients: 4 in the carotid arteries only, 3 in the brain only, and 3 in both the brain and carotid arteries. In those with carotid uptake, 4 participants had >50% stenosis and 3 had nonstenotic disease. One case had bilateral stenotic disease (>70%), but only the culprit carotid artery demonstrated 18 F-GP1 uptake. The average uptake was higher in the culprit (median maximum target-to-background ratio, 1.55 [interquartile range, 1.26–1.82]) compared with the contralateral nonculprit carotid artery (maximum target-to-background ratio, 1.22 [1.19–1.6]). In those with brain 18 F-GP1 uptake (maximum target-to-background ratio, 6.45 [4.89–7.65]), areas of acute infarction on computed tomography correlated with brain 18 F-GP1 uptake in 6 cases. Ex vivo autoradiography of postmortem infarcted brain tissue showed focal uptake corresponding to intraluminal thrombus within the culprit vessel and downstream microvasculature. There was also evidence of diffuse uptake within some of the infarcted brain tissue reflecting parenchymal petechial hemorrhage. CONCLUSIONS: 18 F-GP1 positron emission tomography and computed tomography angiography is a novel noninvasive method of identifying in vivo cerebrovascular thrombosis, which holds major promise in understanding the role and origin of thrombosis in stroke. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03943966.


  • Noninvasive In Vivo Coronary Artery Thrombus Imaging

    by Evangelos Tzolos, Rong Bing, Jack Andrews, Mark G. MacAskill, Adriana A.S. Tavares, Gillian Macnaught, Tim Clark, Nicholas L. Mills, Takeshi Fujisawa, Jennifer Nash, et al.


  • Interplay of tau and functional network connectivity in progressive supranuclear palsy: a [18F]PI-2620 PET/MRI study

    by Gayane Aghakhanyan, M. Rullmann, J. Rumpf, M. L. Schroeter, C. Scherlach, M. Patt, M. Brendel, N. Koglin, A. W. Stephens, J. Classen, et al.

    Purpose Progressive supranuclear palsy (PSP) is primary 4-repeat tauopathy. Evidence spanning from imaging studies indicate aberrant connectivity in PSPs. Our goal was to assess functional connectivity network alterations in PSP patients and the potential link between regional tau-burden and network-level functional connectivity using the next-generation tau PET tracer [18F]PI-2620 and resting-state functional MRI (fMRI). Material and methods Twenty-four probable PSP patients (70.9 ± 6.9 years, 13 female), including 14 Richardson syndrome (RS) and 10 non-RS phenotypes, underwent [18F]PI-2620 PET/MRI imaging. Distribution volume ratios (DVRs) were estimated using non-invasive pharmacokinetic modeling. Resting-state fMRI was also acquired in these patients as well as in thirteen older non-AD MCI reference group (64 ± 9 years, 4 female). The functional network was constructed using 141 by 141 region-to-region functional connectivity metrics (RRC) and network-based statistic was carried out (connection threshold p < 0.001, cluster threshold pFDR < 0.05). Results In total, 9870 functional connections were analyzed. PSPs compared to aged non-AD MCI reference group expressed aberrant connectivity evidenced by the significant NBS network consisting of 89 ROIs and 118 connections among them (NBS mass 4226, pFDR < 0.05). Tau load in the right globus pallidus externus (GPe) and left dentate nucleus (DN) showed significant effects on functional network connectivity. The network linked with increased tau load in the right GPe was associated with hyperconnectivity of low-range intra-opercular connections (NBS mass 356, pFDR < 0.05), while the network linked with increased tau load in the left cerebellar DN was associated with cerebellar hyperconnectivity and cortico-cerebellar hypoconnectivity (NBS mass 517, pFDR < 0.05). Conclusions PSP patients show altered functional connectivity. Network incorporating deep gray matter structures demonstrate hypoconnectivity, cerebellum hyperconnectivity, while cortico-cortical connections show variable changes. Tau load in the right GPe and left DN is associated with functional networks which strengthen low-scale intra-opercular and intra-cerebellar connections and weaken opercular-cerebellar connections. These findings support the concept of tau load-dependent functional network changes in PSP, by that providing evidence for downstream effects of neuropathology on brain functionality in this primary tauopathy.


  • 18F-PI-2620 Tau PET Improves the Imaging Diagnosis of Progressive Supranuclear Palsy

    by Konstantin Messerschmidt, Henryk Barthel, Matthias Brendel, Cordula Scherlach, Karl-Titus Hoffmann, Boris-Stephan Rauchmann, Michael Rullmann, Kenneth Marek, Victor L. Villemagne, Jost-Julian Rumpf, et al.

    Progressive supranuclear palsy (PSP) is a 4-repeat tauopathy movement disorder which can be imaged by the tau positron emission tomography (PET) tracer 18F-PI-2620. The in vivo diagnosis is currently established on clinical grounds and supported by midbrain atrophy estimation in structural magnetic resonance imaging (MRI). Here, we investigate whether 18F-PI-2620 tau PET has the potential to improve the imaging diagnosis of PSP. Methods: In this multi-center observational study, dynamic (0-60min p.i.) 18F-PI-2620 PET and structural MRI data of 36 patients with PSP, 22 with PSP-Richardson’s syndrome (PSP-RS) and 14 with clinical phenotypes other than RS, i.e. variant PSP (vPSP), and those of 10 age-matched healthy controls (HCs) were analyzed. The PET data underwent kinetic modeling which resulted in distribution volume ratio (DVR) images. These and the MRI images were visually assessed by three blinded experts each for typical PSP signs. Furthermore, established midbrain atrophy parameters were measured in structural MRI, and regional DVRs in typical tau-in-PSP target regions in the PET data. Results: Visual assessments discriminated PSP patients and HCs with an accuracy of 63% for MRI, and 80% for the combination of MRI and 18F-PI-2620 PET. As compared to patients of the PSP-RS subgroup, those of the vPSP subgroup profited more in terms of sensitivity from the addition of the visual 18F-PI-2620 PET to the visual MRI information (35% vs. 22%). In quantitative image evaluation, midbrain /pons area ratio and globus pallidus DVRs discriminated best between the PSP patients and HCs, with sensitivities/specificities of 83/90% for MRI, and 94/100% for the combination of MRI and 18F-PI-2620 PET. The gain of sensitivity by adding 18F-PI-2620 PET to MRI data was more marked in clinically less-affected as compared to more-affected patients (37% vs. 19% for visual, and 16% vs. 12% for quantitative image evaluation). Conclusion: These results provide evidence for an improved imaging-based PSP diagnosis by adding 18F-PI-2620 tau PET to structural MRI. This approach seems to be particularly promising at earlier disease stages and could be of value both for improving early clinical PSP diagnosis and for enriching PSP cohorts for trials of disease-modifying drugs.